QCOR No one will go home short for the weekend...watch for a spike
QCOR is a commercial-stage biopharma company. It sells HP Acthar Gel, an injectable drug, which helps patients with difficult-to-treat medical conditions. It's seen as a bit of a wonder drug because it seems to be effective on so many parts of the body. Acthar treats autoimmune and inflammatory conditions by binding to melanocortin receptors which are located throughout the body. Acthar is FDA-approved for 19 indications. Of the 19, QCOR currently generates revenue from multiple sclerosis (MS) flare-ups, infantile spasms (IS), nephrotic syndrome (NS, this is a very lucrative market) and QCOR recently branched into rheumatology (dermatomyositis, polymyositis, lupus, rheumatoid arthritis and psoriatic arthritis). There have been concerns about insurance reimbursement as the drug is very expensive ($100K+) but surprisingly strong unit sales in Q2 led to a jump in the stock last week. The company is growing strongly, is profitable, debt free and cash flow positive. QCOR already reported Q2 results.